INSTRUCTIONS Allergic rhinitis: Diagnosis through management
* To take the test online, go to our secure website at http://www.nursingcenter.com/ce/NP.
* On the print form, record your answers in the test answer section of the CE enrollment form on page 29. Each question has only one correct answer. You may make copies of these forms.
* Complete the registration information and course evaluation. Mail the completed form and registration fee of $21.95 to: Lippincott Williams & Wilkins, CE Group, 74 Brick Blvd., Bldg. 4, Suite 206, Brick, NJ 08723. We will mail your certificate in 4 to 6 weeks. For faster service, include a fax number and we will fax your certificate within 2 business days of receiving your enrollment form.
* You will receive your CE certificate of earned contact hours and an answer key to review your results.There is no minimum passing grade.
* Registration deadline is April 30, 2016.
DISCOUNTS and CUSTOMER SERVICE
* Send two or more tests in any nursing journal published by Lippincott Williams & Wilkins together and deduct $0.95 from the price of each test.
* We also offer CE accounts for hospitals and other healthcare facilities on nursingcenter.com. Call 1-800-787-8985 for details.
Lippincott Williams & Wilkins, publisher of The Nurse Practitioner journal, will award 2.4 contact hours for this continuing nursing education activity.
Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 2.4 contact hours. Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia and Florida #50–1223.
Your certificate is valid in all states. This activity has been assigned 1.5 pharmacology credits.
The ANCC's accreditation status of Lippincott Williams & Wilkins Department of Continuing Education refers only to its continuing nursing educational activities and does not imply Commission on Accreditation approval or endorsement of any commercial product.
Allergic rhinitis: Diagnosis through management
General Purpose: The purpose of this learning activity is to provide information about the pathophysiology, diagnosis, and treatment of AR. Learning Objectives: After reading this article and taking this test, you should be able to: 1. Explain the pathophysiology of AR. 2. Describe the clinical presentation, assessment, and diagnostic testing for AR. 3. Select evidence-based treatment approaches for AR.
1. AR is
a. caused by repeated exposure to histamines.
b. an abnormal immunologic response.
c. mediated by immunoglobulin G.
d. a hypersensitivity disorder of the entire respiratory system.
2. An atopic patient
a. has no allergies.
b. can exhibit an immune response.
c. has developed a skin rash.
d. can suppress an immune response to allergens.
a. are released by stimulated mast cells.
b. constitute an early phase response in AR.
c. cause a cessation of symptoms.
d. inhibit the action of eosinophils.
4. Which statement accurately differentiates SAR from PAR?
a. Patients with SAR are more likely to experience symptom relief by keeping pets out of the bedroom.
b. Dust mites are more likely to cause SAR.
c. Patients with PAR are often more symptomatic outdoors.
d. SAR is more often associated with the release of pollens.
5. When assessing for AR, which of the following is the least relevant finding in the patient history?
a. exposure to respiratory irritants
b. age of onset of symptoms
c. deficiencies associated with smell
d. environmental conditions
6. Physical exam of the patient with AR reveals
a. infraorbital lightening of the skin.
b. enlarged inferior turbinates and clear watery discharge.
c. a reddened cobblestone appearance of the inferior turbinates.
d. ruddy nasal mucosa.
7. Which statement about acute infectious rhinosinusitis is true?
a. A common symptom is purulent nasal discharge.
b. Bacterial rhinosinusitis symptoms resolve in 7–10 days.
c. Viral upper respiratory infection symptoms persist beyond 10 days.
d. It is usually caused by bacteria.
8. Which total serum IgE level is most suggestive of an allergy?
a. 10 units/mL
b. 50 units/mL
c. 100 units/mL
d. 480 units/mL
9. Skin testing for AR
a. is the least sensitive diagnostic methodology.
b. can be performed I.using a histamine solution.
c. causes the antigen to bind to the surface of mast cells and release histamine.
d. causes leukocytes to releases leukotrienes.
10. During RAST testing,
a. a local skin reaction confirms allergen sensitivity.
b. nasal swabs are examined for presence of leukocytes.
c. serum is incubated with tagged antibodies of suspected antigens.
d. allergen sensitivity is indicated by the presence of serum eosinophils.
11. Which of the following is among the most problematic allergens in the home?
b. synthetic fibers
12. Which is a second-generation oral antihistamine?
13. Which statement about topical nasal antihistamines is accurate?
a. They are less effective than oral antihistamines.
b. They have a slow onset of action.
c. They have a fast onset of action.
d. They provide poor control of sneezing.
14. Topical decongestants can cause
b. bradycardia and sedation.
c. increased blood flow to nasal vascular tissue.
15. Cromolyn sodium
a. is prescribed orally once a day.
b. is more effective in reducing allergic symptoms than antihistamines.
c. has a long half-life.
d. is a mast cell stabilizer with limited efficacy.
16. When corticosteroids are used for symptoms of AR,
a. they are only effective for treating nasal decongestion.
b. they cannot be given parenterally.
c. topical use results in a high incidence of significant adverse reactions.
d. topical application is often used as primary first-line therapy.
17. Ipratropium bromide
a. is used to relieve nasal congestion.
b. is a topical anticholinergic that reduces the volume of rhinorrhea.
c. inhibits the release of histamine in patients with AR.
d. can be converted into methamphetamine.